As expected, CD5+CD19+ cells (CLL B cells) were largely absent from control PBMCs and could be detected at varying frequencies in samples from patients with CLL, irrespective of SAMHD1 genotype (Figures 5B, 5C, S4C, and S4D). This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.